Oncoclínicas (B3: ONCO3) financial statements
The consolidated income statement, balance sheet and cash flow statement of Oncoclínicas for its last 6 fiscal years, as filed with the regulator, in millions of Brazilian reais. At the end of fiscal 2025 it had BRL 7,131m in total assets and BRL 900.9m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | BRL 5,739m | BRL 6,227m | BRL 5,489m | BRL 4,088m | BRL 2,702m | BRL 2,035m |
| Cost of sales | BRL 3,953m | BRL 4,167m | BRL 3,560m | BRL 2,636m | BRL 1,833m | BRL 1,400m |
| Gross profit | BRL 1,786m | BRL 2,060m | BRL 1,929m | BRL 1,452m | BRL 868.8m | BRL 635.7m |
| Operating profit | −BRL 1,990m | −BRL 119.9m | BRL 758.0m | BRL 470.6m | BRL 177.2m | BRL 19.6m |
| Profit before tax | −BRL 3,163m | −BRL 656.9m | BRL 302.5m | BRL 121.5m | BRL 62.3m | −BRL 57.1m |
| Income tax | BRL 508.5m | BRL 60.6m | −BRL 10.0m | BRL 7.8m | BRL 84.8m | BRL 68.1m |
| Net profit | −BRL 3,624m | −BRL 646.2m | BRL 223.6m | BRL 46.3m | −BRL 46.9m | −BRL 159.6m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total assets | BRL 7,131m | BRL 11,202m | BRL 9,181m | BRL 8,220m | BRL 6,032m | BRL 3,363m |
| Current assets | BRL 2,896m | BRL 4,661m | BRL 3,105m | BRL 2,827m | BRL 2,871m | BRL 1,412m |
| Cash | BRL 509.5m | BRL 550.7m | BRL 550.7m | BRL 263.2m | BRL 536.8m | BRL 740.8m |
| Total liabilities | BRL 6,068m | BRL 7,820m | BRL 6,502m | BRL 5,587m | BRL 3,727m | BRL 2,685m |
| Current liabilities | BRL 5,202m | BRL 2,453m | BRL 1,816m | BRL 1,883m | BRL 1,191m | BRL 1,014m |
| Equity | BRL 900.9m | BRL 3,146m | BRL 2,301m | BRL 2,118m | BRL 1,854m | BRL 399.8m |
| Equity including minorities | BRL 1,062m | BRL 3,382m | BRL 2,679m | BRL 2,632m | BRL 2,305m | BRL 677.3m |
| Minority interests | BRL 161.5m | BRL 236.1m | BRL 378.1m | BRL 514.7m | BRL 450.9m | BRL 277.5m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | −BRL 118.6m | −BRL 184.9m | −BRL 51.6m | −BRL 271.6m | −BRL 9.3m | BRL 97.6m |
| Investing cash flow | BRL 793.0m | −BRL 1,721m | BRL 227.8m | −BRL 408.7m | −BRL 2,030m | −BRL 355.2m |
| Financing cash flow | −BRL 717.8m | BRL 1,905m | BRL 111.4m | BRL 407.1m | BRL 1,835m | BRL 551.1m |
| Dividends paid | −BRL 36.8m | −BRL 11.7m | −BRL 59.7m | −BRL 18.3m | −BRL 26.4m | −BRL 45.2m |
Where each figure comes from
From the annual financial statements (DFP) that Oncoclínicas files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Oncoclínicas page.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.